These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 23891944)

  • 21. Visceral leishmaniasis affects liver and spleen concentrations of amphotericin B following administration to mice.
    Gershkovich P; Wasan EK; Sivak O; Li R; Zhu X; Werbovetz KA; Tidwell RR; Clement JG; Thornton SJ; Wasan KM
    J Antimicrob Chemother; 2010 Mar; 65(3):535-7. PubMed ID: 20026611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of in vitro and in vivo Efficacy of a Novel Amphotericin B-Loaded Nanostructured Lipid Carrier in the Treatment of
    Rebouças-Silva J; Tadini MC; Devequi-Nunes D; Mansur AL; S Silveira-Mattos P; I de Oliveira C; R Formiga F; Berretta AA; Marquele-Oliveira F; Borges VM
    Int J Nanomedicine; 2020; 15():8659-8672. PubMed ID: 33177824
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity of Amphotericin B-Loaded Chitosan Nanoparticles against Experimental Cutaneous Leishmaniasis.
    Riezk A; Van Bocxlaer K; Yardley V; Murdan S; Croft SL
    Molecules; 2020 Sep; 25(17):. PubMed ID: 32887341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gelatin coated hybrid lipid nanoparticles for oral delivery of amphotericin B.
    Jain S; Valvi PU; Swarnakar NK; Thanki K
    Mol Pharm; 2012 Sep; 9(9):2542-53. PubMed ID: 22845020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Covalent functionalized self-assembled lipo-polymerosome bearing amphotericin B for better management of leishmaniasis and its toxicity evaluation.
    Gupta PK; Jaiswal AK; Kumar V; Verma A; Dwivedi P; Dube A; Mishra PR
    Mol Pharm; 2014 Mar; 11(3):951-63. PubMed ID: 24495144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Poloxamer 407 (Pluronic(®) F127)-based polymeric micelles for amphotericin B: In vitro biological activity, toxicity and in vivo therapeutic efficacy against murine tegumentary leishmaniasis.
    Mendonça DV; Lage LM; Lage DP; Chávez-Fumagalli MA; Ludolf F; Roatt BM; Menezes-Souza D; Faraco AA; Castilho RO; Tavares CA; Barichello JM; Duarte MC; Coelho EA
    Exp Parasitol; 2016 Oct; 169():34-42. PubMed ID: 27427166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New amphotericin B-gamma cyclodextrin formulation for topical use with synergistic activity against diverse fungal species and Leishmania spp.
    Ruiz HK; Serrano DR; Dea-Ayuela MA; Bilbao-Ramos PE; Bolás-Fernández F; Torrado JJ; Molero G
    Int J Pharm; 2014 Oct; 473(1-2):148-57. PubMed ID: 24998510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relation between Skin Pharmacokinetics and Efficacy in AmBisome Treatment of Murine Cutaneous Leishmaniasis.
    Wijnant GJ; Van Bocxlaer K; Yardley V; Harris A; Murdan S; Croft SL
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Parasite burden in Leishmania (Leishmania) amazonensis-infected mice: validation of luciferase as a quantitative tool.
    Reimão JQ; Trinconi CT; Yokoyama-Yasunaka JK; Miguel DC; Kalil SP; Uliana SR
    J Microbiol Methods; 2013 May; 93(2):95-101. PubMed ID: 23466934
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nanoemulsions containing amphotericin b and paromomycin for the treatment of cutaneous leishmaniasis.
    Cunha NFC; de Siqueira LBO; Garcia AR; Rodrigues IA; Matos APDS; Júnior ER; Monteiro MSSB
    Acta Trop; 2024 Jun; 254():107189. PubMed ID: 38522630
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacious topical treatment for murine cutaneous leishmaniasis with ethanolic formulations of amphotericin B.
    Frankenburg S; Glick D; Klaus S; Barenholz Y
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3092-6. PubMed ID: 9835496
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hemolytic and pharmacokinetic studies of liposomal and particulate amphotericin B formulations.
    Serrano DR; Hernández L; Fleire L; González-Alvarez I; Montoya A; Ballesteros MP; Dea-Ayuela MA; Miró G; Bolás-Fernández F; Torrado JJ
    Int J Pharm; 2013 Apr; 447(1-2):38-46. PubMed ID: 23438978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro study of the anti-leishmanial activity of biodegradable nanoparticles.
    Venier-Julienne MC; Vouldoukis I; Monjour L; Benoit JP
    J Drug Target; 1995; 3(1):23-9. PubMed ID: 7655817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bioinspired Calcium Phosphate Nanoparticles Featuring as Efficient Carrier and Prompter for Macrophage Intervention in Experimental Leishmaniasis.
    Chaurasia M; Singh PK; Jaiswal AK; Kumar A; Pawar VK; Dube A; Paliwal SK; Chourasia MK
    Pharm Res; 2016 Nov; 33(11):2617-29. PubMed ID: 27401407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antileishmanial activity of nano-amphotericin B deoxycholate.
    Manandhar KD; Yadav TP; Prajapati VK; Kumar S; Rai M; Dube A; Srivastava ON; Sundar S
    J Antimicrob Chemother; 2008 Aug; 62(2):376-80. PubMed ID: 18453526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of targeted 1,2-diacyl-sn-glycero-3-phospho-l-serine-coated gelatin nanoparticles loaded with amphotericin B for improved in vitro and in vivo effect in leishmaniasis.
    Khatik R; Dwivedi P; Khare P; Kansal S; Dube A; Mishra PR; Dwivedi AK
    Expert Opin Drug Deliv; 2014 May; 11(5):633-46. PubMed ID: 24606222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nanodisk-associated amphotericin B clears Leishmania major cutaneous infection in susceptible BALB/c mice.
    Nelson KG; Bishop JV; Ryan RO; Titus R
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1238-44. PubMed ID: 16569834
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amphotericin B-Loaded Emulgel: Effect of Chemical Enhancers on the Release Profile and Antileishmanial Activity In Vitro.
    Pinheiro IM; Carvalho IPS; Neto JAT; Lopes GLN; de Sousa Coêlho E; Sobrinho-Júnior EPC; de Moraes Alves MM; de Amorim Carvalho FA; Carvalho ALM
    AAPS PharmSciTech; 2019 Feb; 20(3):122. PubMed ID: 30805739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica.
    Solomon M; Pavlotsky F; Leshem E; Ephros M; Trau H; Schwartz E
    J Eur Acad Dermatol Venereol; 2011 Aug; 25(8):973-7. PubMed ID: 21129042
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunization against leishmaniasis by PLGA nanospheres loaded with an experimental autoclaved Leishmania major (ALM) and Quillaja saponins.
    Tafaghodi M; Eskandari M; Kharazizadeh M; Khamesipour A; Jaafari MR
    Trop Biomed; 2010 Dec; 27(3):639-50. PubMed ID: 21399606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.